Transporter-targeted Methods Of Diagnosis And Treatment

  • Published: Dec 21, 2007
  • Earliest Priority: Sep 30 2005
  • Family: 3
  • Cited Works: 5
  • Cited by: 0
  • Cites: 4
  • Additional Info: Cited Works Full text

The text shown here has been derived from the original document's published images via a process of ´optical character recognition (OCR). Due to variations in image quality, and the imperfect nature of OCR process, this text may not be 100% accurate. To view the original published images, please refer to the PDF.


(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 April 2007 (12.04.2007)
(51) International Patent Classification: GOlN 33/574 (2006.01) (21) International Application Number: PCT/US2006/038003 (22) International Filing Date: 27 September 2006 (27.09.2006) (25) Filing Language: (26) Publication Language: (30) Priority Data: 60/722,189

PCT

(10) International Publication Number

W O 2007/041268 A3
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FT, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV,LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

English English

30 September 2005 (30.09.2005)

US

(71) Applicant (for all designated States except US): XENOPORT, INC. [US/US]; 3410 Central Expressway, Santa Clara, California 9505 1-0703 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ZERANGUE, Noa [US/US] ; 773 Sequoia Drive, Sunnyvale, California 94086 (US). DOWER, William, J. [US/US]; 2307 Branner Drive, Menlo Park, California 94025 (US). (74) Agents: HAYNES, Jennifer et al; Two Embarcadero Center, 8th Floor, San Francisco, California 941 11-3834 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published: — with international search report — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments — with sequence listing part of description published s ep a rately in electronic form and available upon request from the International Bureau
(88) Date of publication of the international search report: 2 1 December 2007
For two-letter codes and other abbreviations, refer to the "G u id ance Notes o n Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TRANSPORTER-TARGETED METHODS OF DIAGNOSIS AND TREATMENT (57) Abstract: Methods of treating a disease in a patient, methods of determining the presence of a disease in a patient, methods of de ter m in ing whether a disease in a patient i s suitable to b e treated with a therapeutic agent, and methods of monitoring treatment of a disease in a patient comprising determining a level of expression of a transporter in cells of a tissue associated with the disease are disclosed. The methods include administering to a patient a diagnostic conjugate and/or therapeutic conjugate that are substrates for a transporter expressed b y cells of a tissue associated with the disease. Kits comprising a diagnostic composition comprising a diagnostic conjugate that i s a transporter substrate are also disclosed. I n particular, methods and kits useful for diagnosing and treating cancer are disclosed.

(1)

-0 5 10 15 Treatment Duration (days)

A . CLASSIFICATION OF SUBJECT MATTER

INV.

G01N33/574

According t o International Patent Classification (IPC) o r t o both national classification and IPC
B . FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

GOlN

Documentation searched other than minimum documentation to the extent that such documents are included i n the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal,

WPI Data, BIOSIS, EMBASE

C . DOCUMENTS CONSIDERED TO B E RELEVANT

Category *

Citation of document, with indication, where appropriate, of the relevant passages

Relevant t o claim No

MACHEDA MARIA L ET AL: "Molecular and cellular regulation o f glucose transporter (GLUT) proteins in cancer" JOURNAL O F CELLULAR PHYSIOLOGY, vol. 202, no. 3 , March 2005 (2005-03), pages 654-662, XP002439461 ISSN: 0021-9541 the whole document W O 2004/096841 A l (CENTRE NAT RECH SCIENT [FR]; UNIVERSITE MONTPELLIER I I [FR]; BATTINI J ) 1 1 November 2004 (2004-11-11) the whole document W O 96/41193 A (SINAI SCHOOL MEDICINE [US]; BURSTEIN DAVID E [US]; HABER RICHARD S [US) 19 December 1996 (1996-12-19) the whole document -/-Further documents are listed i n the continuation of Box C
*

1-22

1-21

1-20

See patent family annex 'T' later document published after the international filing date o r pnority date and not i n conflict with the application but cited to understand the principle o r theory underlying the invention 'X' document of particular relevance, the claimed invention cannot be considered novel o r cannot be considered to involve a n inventive step when the document is taken alone 'Y' document of particular relevance, the claimed invention cannot be considered t o involve a n inventive step when the document is combined with one o r more other such docu¬ ments, such combination being obvious to a person skilled in the art ■ " document member of the same patent family Date of mailing of the international search report

Special categories of cited documents

'A' document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published o n o r after the international filing date L " document which may throw doubts o n pπo πt y claιm(s) o r which is cited to establish the publication date of another citation o r other special reason (as specified) "O - document referring t o a n oral disclosure, use, exhibition o r other means "P" document published prior t o the international filing date but later than the prionty date claimed
Date of the actual completion of the international search

2 7 June 2007
Name and mailing address of the ISA/ European Patent Office, P B 5818 Patentlaan 2 NL - 2280 HV Rιjswi|k TeI (+31-70) 340-2040, Tx 3 1 651 epo nl, Fax (+31-70) 340-3016
Foim PCT/ISA/210 (second sheet) (April 2005)

26/10/2007
Authorized officer

Werner, Andreas

C(Continuation).
Category

DOCUMENTS CONSIDERED TO BE RELEVANT

Citation of document, with indication, where appropriate, of the relevant passages

Relevant to claim No

KUECK ANGELA ET AL: "Inhibition o f glycolysis: Novel therapy for ovarian cancer." PROCEEDINGS O F THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 46, April 2005 (2005-04), page 725, XP002439462 & 96TH ANNUAL MEETING O F THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; ANAHEIM, CA, USA; APRIL 16 -20, 2005 ISSN: 0197-016X the whole document SMITH TAD: "FACILITATIVE GLUCOSE TRANSPORTER EXPRESSION IN HUMAN CANCER TISSUE" BRITISH JOURNAL O F BIOMEDICAL SCIENCE, ROYAL SOCIETY O F MEDICINE SERVICES, LONDON, GB, vol. 56, no. 4 , 1999, pages 285-292, XP009064446 ISSN: 0967-4845 the whole document W O 03/082301 A (THRESHOLD PHARMACEUTICALS INC [US]) 9 October 2003 (2003-10-09) paragraph [0007] - paragraph [0016] HALMOS T ET AL: "Synthesis o f 0-methylsulfonyl derivatives o f D-glucose a s potential alkylating agents for targeted drug delivery t o the brain. Evaluation of their interaction with the human erythrocyte GLUTl hexose transporter" CARBOHYDRATE RESEARCH, ELSEVIER SCIENTIFIC PUBLISHING COMPANY. AMSTERDAM, NL, vol. 299, no. 1-2, 1997, pages 15-21, XP002356678 ISSN: 0008-6215 the whole document MENDEZ LUIS E ET AL: "Expression o f glucose transporter-1 in cervical cancer and its precursors" GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 86, no. 2 , August 2002 (2002-08), pages 138-143, XP002254294 ISSN: 0090-8258 the whole document
P ,X

1-5,7-21

1-22

1-22

1-22

1-22

W O 2005/117931 A (XENOPORT INC [US]; ZERANGUE NOA [US]; GANGAKHEDKAR ARCHANA [US]) 15 December 2005 (2005-12-15) the whole document

1-22

Form PCT/ISA/210 (continuation of second sheet) (April 2005)

International Application No. PCT/US2006

/038003

FURTHER INFORMATION CONTINUED FROM

PCT/ISA/

210

Continuation

o f Box II. 1

Claims 1-6, 1 4 and 18 are directed t o methods o f treatment by therapy o f the human/animal body, and claims 1-18 are directed t o methods comprising the provision o f cells o f a tissue o f a patient, which i s considered t o comprise a surgical step carried out o n the human/animal body. Consequently, the search for claims 1-18 has been carried out and based o n the alleged effects o f the compounds/compositions.

n erna iona app ica ion

o

INTERNATIONAL

SEARCH

REPORT

PCT/US2006/038003

Box I l Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established i n respect of certain claims under Article 17(2)(a) for the following reasons

1 I X I Claims Nos
because they relate to subject matter not required to be searched by this Authority, namely:

see FURTHER INFORMATION sheet PCT/ISA/210

D

Claims Nos.

because they relate to parts of the International Application that do not comply with the prescribed requirements t o such a n extent that no meaningful International Search can be carried out, specifically

Claims Nos because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows

see additi onal sheet

□

A s all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

A s all searchable claims could be searched without effort justifying a n additional fee, this Authority did not invite payment of any additional fee

3. I I A s only some of the required additional search fees were timely paid by the applicant, this International Search Report 1 — ' covers only those claims for which fees were paid, specifically claims Nos.

4 . I Y I No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims, it is covered by claims Nos.:

1-22 ( i n part)

Remark o n Protest

I

I The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees

I
Form PCT/ISA/210 (continuaton of first sheet (2)) (January 2004)

International Application No. PCT/US2006

/038003

FURTHER INFORMATION CONTINUED FROM

POT/ISA/

210

This International Searching Authority found multiple (groups of) inventions i n this international application, a s follows:
1.

claims: 1-22 (in part) Methods o f screening cells for the expression o f human sugar transporter GLUTl and selecting a therapeutic agent being a substrate for GLUTl, wherein said agent i s therapeutically effective against cancer, pref. breast, lung, ovary or colon cancer; methods o f determining the expression level of GLUTl based o n measuring the uptake o r transport o f a diagnostic conjugate o r agent being a substrate for GLUTl; methods o f determining the presence o f cancer i n a patient, comprising measuring the relative expression level of GLUTl i n cells o f a tissue of a patient and comparing i t t o a reference; methods o f determining whether cancer i s suitable t o be treated with a therapeutic agent being a substrate for GLUTl, comprising measuring GLUTl expression and comparing it t o a minimum predetermined expression level; methods o f monitoring treatment o f cancer i n a patient by measuring and comparing the expression level o f GLUTl before and after treatment; kit, comprising a diagnostic conjugate being a substrate for GLUTl and a pharmaceutically acceptable vehicle; diagnostic kit for selecting a therapeutic agent for treating cancer, comprising a first diagnostic agent being a substrate for GLUTl and a pharmaceutically acceptable vehicle, and a second diagnostic agent being a substrate for a second transporter and a pharmaceutically acceptable vehicle.

2.

claims: 1-22 (in part) Same a s above, but limited t o human sugar transporter
GLUT3.

3.

claims: 1-22 (in part) Same a s above, but limited t o human sugar transporter
GLUT5.

4.

claims: 1-22 (in part) Same a s above, but limited t o human monocarboxyl ate transporter MCTl.

5.

claims: 1-22 (in part) Same a s above, but limited t o human monocarboxyl ate transporter MCT4.

international Application No. PCT/US2006

/038003

RJRTHER INFORMATION CONTINUED FROM

PCT/ISA/

2 10

6 . claims:

1-22 (in part)

Same a s above, but limited t o human amino acid transporter
LATl.

7 . claims:

1-22 (in part)

Same a s above, but limited t o human amino acid transporter
F.

8 . claims:

1-22 (in part)

Same a s above, but limited t o human amino acid transporter
G.

9 . claims:

1-22 (in part)

Same a s above, but limited t o human amino acid transporter
H.

10.

claims: 1-22 (in part) Same a s above, but limited t o human amino acid transporter
I.

11. claims:

1-22 (in part)

Same a s above, but limited t o human amino acid transporter
J.

12. claims:

1-22 (in part)

Same a s above, but limited t o human amino acid transporter
K.

13.

claims: 1-22 (in part) Same a s above, but limited t o human amino acid transporter
L.

14.

claims: 1-22 (in part) Same a s above, but limited t o human amino acid transporter
M.

International Application No. PCT/US2006

/038003

FURTHER

INFORMATION
15. c l aims:

CONTINUED 1-22

FROM

f 'CT/ISA/ 210

(in part) but 1 im i ted

Same
N.

a s above,

t o human amino acid transporter

16. c l aims:

1-22 (in part)
a s above, but 1 im i ted

Same 0.

t o human amino acid transporter

17. c l aims:

1-22

(in part) but 1 im i ted

Same

a s above,

t o human nucleoside transporter

ENT-I.

18. c l aims:

1-22

(in part) but 1 im i ted

Same
Q.

a s above,

t o human nucleoside transporter

19. c l aims:

1-22

(in part) 1 im i ted

Same a s above, but transporter R.

t o human organic anion

20.

c l aims:

1-22

(in part)

Same a s above, but transporter S.

1im i ted

t o human organic anion

21.

C l aims:

1-22

(in part) 1 im i ted

Same a s above, but transporter T.

t o human organic anion

22.

c l aims:

1-22

(in part) but 1 im i ted

Same

a s above,
U.

t o human organic anion

transporter

23.

c l aims:

1-22 (in part)
t o human transporter SMVT.

Same a s above, but 1imited

24.

c l aims:

1-22 (in part)

International Application No. PCT/US2006

/038003

FURTHER INFORMATION CONTINUED FROM

POT/ISA/

210
W.

Same a s above, but limited t o human transporter

25. claims:

1-22 (in part)
X.

Same a s above, but limited t o human transporter

26. claims:

1-22 (in part)
Y.

Same a s above, but limited t o human transporter

Patent document cited in search report

Publication date

Patent family member(s)

Publication date

WO 2004096841
WO 9641193

Al

11-11-2004 19-12-1996

NONE
AU CA
EP JP US

A

5990096 2223010 0834077 11511245 5698410

A
Al Al

T A

30-12-1996 19-12-1996 08-04-1998 28-09-1999 16-12-1997 13-10-2003

WO 03082301 WO 2005117931

A A

09-10-2003 15-12-2005

AU

2003230750 A l

NONE

Form PCT/ISA/210 (patent family annex) (April 2005)



Feedback